Apnimed, Inc. (APMD)
APMDDrugs in Pipeline
21
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
Get an email about APMD's next catalysts
Track Apnimed, Inc. (APMD) (APMD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming, 0 past
APMD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
FDA PDUFA Date AD109 (Oxnimbi) (standard)
For Obstructive sleep apnea (OSA). NDA filing. Extracted from SEC filing: EX-99.1
SourceUpcoming FDA decisions
AD109
OSA - Obstructive Sleep Apnea
Mannitol
Sleep Apnea, Obstructive
AD128
Obstructive Sleep Apnea
Period A
OSA
SAS0421a
Sleep Apnea
Dosing 1: Atomoxetine
Obstructive Sleep Apnea
AD182
Obstructive Sleep Apnea
AD109 dose1- A
Obstructive Sleep Apnea
R-oxybutynin
Obstructive Sleep Apnea
SAS0421b
Sleep Apnea
AD504
Obstructive Sleep Apnea
Period B
OSA
SAS0421c
Sleep Apnea
AD313
Obstructive Sleep Apnea
Period C
OSA
AD109 dose2- B
Obstructive Sleep Apnea
AD036 Dose 2
Obstructive Sleep Apnea
AD036 Dose 1
Obstructive Sleep Apnea
AD036 Dose 3
Obstructive Sleep Apnea
AD036
Sleep Disordered Breathing
AD113
Obstructive Sleep Apnea
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AD109 | Phase 3 | OSA - Obstructive Sleep Apnea | - | - |
Mannitol | Phase 3 | Sleep Apnea, Obstructive | - | - |
AD128 | Phase 3 | Obstructive Sleep Apnea | - | - |
Period A | Phase 2 | OSA | - | - |
SAS0421a | Phase 2 | Sleep Apnea | - | - |
Dosing 1: Atomoxetine | Phase 2 | Obstructive Sleep Apnea | - | - |
AD182 | Phase 2 | Obstructive Sleep Apnea | - | - |
AD109 dose1- A | Phase 2 | Obstructive Sleep Apnea | - | - |
R-oxybutynin | Phase 2 | Obstructive Sleep Apnea | - | - |
SAS0421b | Phase 2 | Sleep Apnea | - | - |
AD504 | Phase 2 | Obstructive Sleep Apnea | - | - |
Period B | Phase 2 | OSA | - | - |
SAS0421c | Phase 2 | Sleep Apnea | - | - |
AD313 | Phase 2 | Obstructive Sleep Apnea | - | - |
Period C | Phase 2 | OSA | - | - |
AD109 dose2- B | Phase 2 | Obstructive Sleep Apnea | - | - |
AD036 Dose 2 | Phase 2 | Obstructive Sleep Apnea | - | - |
AD036 Dose 1 | Phase 2 | Obstructive Sleep Apnea | - | - |
AD036 Dose 3 | Phase 2 | Obstructive Sleep Apnea | - | - |
AD036 | Phase 2 | Sleep Disordered Breathing | - | - |
AD113 | Phase 2 | Obstructive Sleep Apnea | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Apnimed, Inc. (APMD)'s drug pipeline?→
CatalystAlert tracks 21 drug candidates in Apnimed, Inc. (APMD)'s (APMD) pipeline across Phase 3, Phase 2. Its lead program is AD109 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apnimed, Inc. (APMD)'s next FDA catalyst?→
Apnimed, Inc. (APMD)'s (APMD) next tracked catalyst is a PDUFA date expected February 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APMD biotech catalysts?→
Add APMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apnimed, Inc. (APMD)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.